All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, introduces the panel of speakers and topics explored in the symposium.
Satellite Symposium | Welcome and Introductions
Salles begins by outlining the increase in available therapies we have seen this year, including targeted therapies, BTK inhibitors, venetoclax, PI3 kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, and CAR T-cell therapy. During the symposium, the panel discussed how to make optimal use of these therapies for patients, and it concluded with a round table discussion, where the panel answered live questions.
Satellite Symposium | Welcome and Introductions
If you would like to download the slides from Gilles Salles' introductory presentation, click below.
Download hereUnderstanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox